Evidence map›Paper›PMID 29019086›Full record

ArticleFamilial cancer2018

Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy.

Rainer Fagerholm, Maria Faltinova, Kirsi Aaltonen, Kristiina Aittomäki, Päivi Heikkilä, Mervi Halttunen-Nieminen, Heli Nevanlinna, Carl Blomqvist

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rainer FagerholmDepartment of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, PO Box 700, 00029 HUS,, Helsinki, Finland.
Maria FaltinovaDepartment of Oncology, Helsinki University Hospital and University of Helsinki, PO Box 180, 00029 HUS,, Helsinki, Finland.
Kirsi AaltonenDepartment of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, PO Box 700, 00029 HUS,, Helsinki, Finland.
Kristiina AittomäkiDepartment of Clinical Genetics, Helsinki University Hospital and University of Helsinki, PO Box 160, 00029 HUS,, Helsinki, Finland.
Päivi HeikkiläDepartment of Pathology, Helsinki University Hospital, PO Box 400, 00029 HUS,, Helsinki, Finland.
Mervi Halttunen-NieminenDepartment of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, PO Box 700, 00029 HUS,, Helsinki, Finland.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, Helsinki University Hospital and University of Helsinki, PO Box 700, 00029 HUS,, Helsinki, Finland. heli.nevanlinna@hus.fi.ORCID 0000-0002-0916-2976
Carl BlomqvistDepartment of Oncology, Helsinki University Hospital and University of Helsinki, PO Box 180, 00029 HUS,, Helsinki, Finland.

Funding

Terveyden Tutkimuksen Toimikunta 266528
6 · The paper itself

Abstract

Long term use of postmenopausal hormone therapy (HT) has been reported to increase breast cancer risk. On the other hand, observational studies suggest that breast cancers diagnosed during HT may have a more favorable prognosis. While family history is a risk factor for breast cancer, and genetic factors also influence prognosis, the role of family history in combination with HT use has been little studied. We investigated the relationship between HT, family history, and prognosis in 584 (267 exposed) familial and 952 (460 exposed) non-familial breast cancer cases, using three survival end points: death from breast cancer (BCS), distant disease free survival (DDFS), and local recurrence free survival (LRFS). Among non-familial cases, HT was associated with better BCS (HR 0.63, 95% CI 0.41-0.94; p = 0.025), and DDFS (HR 0.58, 95% CI 0.40-0.85; p = 0.005), with a consistent but not statistically significant effect in LRFS. This effect was not seen in familial cases (HR > 1.0), and family history was found to interact with HT in BCS (p

Indexed as

AgedBreast NeoplasmsDisease-Free SurvivalEstrogen Replacement TherapyFemaleHumansMiddle AgedPrognosisBreast cancerFamily historyHormone replacement therapyObservational studyPrognosisSurvival

Identifiers

PMID29019086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.